Taiwan study reveals HER2 rates in Hard-to-Treat gynecologic cancers
NCT ID NCT06925113
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 37 times
Summary
This study looked at medical records from 509 adults in Taiwan to find out how often advanced cervical, endometrial, and ovarian cancers have a specific marker called HER2 IHC 3+. Researchers also described the patients' health details to better understand who might benefit from newer targeted therapies. No treatments were given—this was purely an information-gathering study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 833, Taiwan
-
Mackay Memorial Hospital
Taipei, 104, Taiwan
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Taichung Veterans General Hospital
Taichung, 407, Taiwan
-
Taipei Veterans General Hospital
Taipei, 112, Taiwan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.